VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. - Wikidata - wikimedia - TriplyDB

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

http://www.wikidata.org/entity/Q37714030

about

Replicon RNA Viral Vectors as Vaccines Pseudotyping lentiviral vectors with lymphocytic choriomeningitis virus glycoproteins for transduction of dendritic cells and in vivo immunization.A Novel Live Pichinde Virus-Based Vaccine Vector Induces Enhanced Humoral and Cellular Immunity after a Booster Dose.Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.Viral and Synthetic RNA Vector Technologies and Applications.Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice.The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

P2860

Q28076639-0E077CE7-EFAF-45A3-AD0E-3E126C0EA3AF Q34719449-C6767CCC-8E36-449B-9346-635BA6664903 Q36736786-6161F2A2-7AA8-4040-9FFD-08358BAE2F0C Q37292354-C4E4FAF5-3622-43F9-9D02-E7C9E94FA4C2 Q37417618-9633235D-7798-40E5-AC5F-9460ABAB7415 Q38885624-DA489AA0-D698-46D4-A73B-481BFA8E58B7 Q40052567-C26B1EC6-B871-46E4-B7EC-5353443AD9E4 Q52677347-4D659C86-01FC-4D1B-8E73-2893A57718A3 Q54378300-92641DD3-63CC-4744-BAD2-72E6BB6620C3 Q55652233-A030FC8E-DC21-4935-800B-3A0FF8D4D59C

P2860

VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.

http://www.wikidata.org/entity/Q37714030

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@en

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@nl

type

label

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@en

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@nl

prefLabel

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@en

VSV-GP: a potent viral vaccine ...... se upon repeated applications.

@nl

P1433

Q37714030-0174F739-33D3-4734-8537-37A30B2FC539

P1476

Q37714030-9501E731-633D-471B-8720-86ADA13747D3

P2093

Q37714030-2B077611-6F19-48CB-B939-3A91B8BD6086

Q37714030-35DF4F51-DCD9-435F-8641-482C083C678F

Q37714030-5585500A-7CA8-48E2-99E9-35943F632736

Q37714030-753A264C-5B0E-4275-BC69-DE09CD88BB5E

Q37714030-964433BC-511A-49D7-A86A-D4961E14F629

Q37714030-A43684ED-8AEA-4315-8697-D8BCD383673B

Q37714030-BF58F47B-2BD0-4D3E-A4B3-197DD50CED96

P2860

Q37714030-090B4691-0DD2-49F3-8552-2CD620D46E3D

Q37714030-0A67DF2E-2E78-4184-8203-EB470E941BDB

Q37714030-1063D88B-EDBF-4CF2-82AD-5C749AD30A8C

Q37714030-12800035-3FF0-4754-81B5-27733BD1B843

Q37714030-14AFC41D-810F-4B30-B1D7-89DC9E42DA74

Q37714030-1DEF93FA-1DE7-4F70-AFF0-F2E13273CCC7

Q37714030-36A74C6B-7493-4461-A32C-E6C122D00CA1

Q37714030-3CC12EDA-9F17-4876-BDA7-8F7B253C6225

Q37714030-3E6E7A02-F258-4622-88D0-9F381C243323

Q37714030-3F96AD22-3EBB-4F40-8C23-77ECBB84384D

P304

Q37714030-41042DF8-6606-4182-95ED-8DE339826E4F

P31

Q37714030-A103FD3A-9A73-40FF-B833-ABEDE0BC40BB

P356

Q37714030-24E8F8F1-C5F7-425B-AF4A-EBD533149729

P407

Q37714030-FA1108BE-1B6D-4F46-BFF3-EE912B88136E

P433

Q37714030-9C274CDA-C2B4-4C07-9A21-DF9321E4803D

P478

Q37714030-41993C34-E61B-42C6-94C3-B3A41156D1FF

P50

Q37714030-47F66060-1BCE-485A-925C-459899AEC921

Q37714030-B6C15A83-E663-46C3-BFE1-042FE4602DF1

Q37714030-D9A54239-5E70-4E01-8154-918BE713B268

P577

Q37714030-5374DA3E-4BF4-4690-9D8E-15A416B00184

P698

Q37714030-C0000468-531E-4A6C-ACDE-717EC0921E50

P932

Q37714030-D6FF32E8-BCB7-4497-9B8A-7FD30C82C4E8

P356

P1433

Journal of Virology

P1476

VSV-GP: a potent viral vaccine ...... nse upon repeated applications

@en

P2093

Alexander Muik

http://www.w3.org/2001/XMLSchema#string

Dorothee von Laer

http://www.w3.org/2001/XMLSchema#string

Florian Kreppel

http://www.w3.org/2001/XMLSchema#string

Lisa Egerer

http://www.w3.org/2001/XMLSchema#string

Reinhard Tober

http://www.w3.org/2001/XMLSchema#string

Sandra Behmüller

http://www.w3.org/2001/XMLSchema#string

Ute Greczmiel

http://www.w3.org/2001/XMLSchema#string

P2860

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

Attenuated vesicular stomatitis viruses as vaccine vectors

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.

Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1

Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates

Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.

Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha

P304

4897-4907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.03276-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P50

Annette Oxenius

P577

2014-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24554655

http://www.w3.org/2001/XMLSchema#string

P932

3993835

http://www.w3.org/2001/XMLSchema#string